Taysha Gene Therapies, Inc.
TSHA
$6.85
$0.030.44%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 7.47M | 9.77M | 6.31M | 8.10M | 7.22M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 7.47M | 9.77M | 6.31M | 8.10M | 7.22M |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 7.47M | 9.77M | 6.31M | 8.10M | 7.22M |
| SG&A Expenses | 35.39M | 33.87M | 31.66M | 31.29M | 30.03M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 140.03M | 120.27M | 108.44M | 97.26M | 90.94M |
| Operating Income | -132.56M | -110.50M | -102.13M | -89.17M | -83.71M |
| Income Before Tax | -129.88M | -109.00M | -99.93M | -92.72M | -86.77M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -129.88 | -109.00 | -99.93 | -92.72 | -86.77 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -129.88M | -109.00M | -99.93M | -92.72M | -86.77M |
| EBIT | -132.56M | -110.50M | -102.13M | -89.17M | -83.71M |
| EBITDA | -131.41M | -109.35M | -100.98M | -88.01M | -82.51M |
| EPS Basic | -0.38 | -0.34 | -0.33 | -0.34 | -0.34 |
| Normalized Basic EPS | -0.22 | -0.20 | -0.19 | -0.18 | -0.18 |
| EPS Diluted | -0.38 | -0.34 | -0.33 | -0.34 | -0.34 |
| Normalized Diluted EPS | -0.22 | -0.20 | -0.19 | -0.18 | -0.18 |
| Average Basic Shares Outstanding | 1.38B | 1.28B | 1.19B | 1.10B | 1.04B |
| Average Diluted Shares Outstanding | 1.38B | 1.28B | 1.19B | 1.10B | 1.04B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |